Poster presented at WCLC 2022 describing the final analysis of RATIONALE-303, a Phase 3 trial comparing tislelizumab versus docetaxel in previously treated advanced NSCLC.

Poster presented at WCLC 2022 describing the preliminary results of PD-L1-positive, locally advanced or metastatic, non-squamous NSCLC cohort H from the Phase 1b SAFFRON-103 trial.

Poster presented at WCLC 2022 describing the preliminary results of PD-L1-positive, locally advanced or metastatic, squamous NSCLC cohort I from the Phase 1b SAFFRON-103 trial.

Poster presented at WCLC 2022 describing the results of a metastatic NSCLC cohort from the phase 1b AdvanTIG-105 trial, showing a promising ORR and acceptable safety profile.

BeiGene is developing a pipeline of oral small molecules and monoclonal antibodies to fight cancer. Get up-to-date with the BeiGene solid tumor pipeline and clinical trials.